Findings

What do systematic reviews say?

5 questions · 10 findings · 2 reviews · Metabolic and Endocrine Disorders · asked by two or more reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 10%Low 5 · 50%Moderate 4 · 40%High 0 · 0%

Summary of findings: insulin detemir vs NPH insulin

All‐cause mortality

2 findings from 2 reviews · compare the 2 reviews

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
4.97 [0.79, 31.38]
9 studies · 3334 participants
Moderate
(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
Peto OR 0.74 [0.2, 2.65]
8 studies · 2328 participants
Low

Insulin glargine vs NPH insulin

HbA1c (%)

2 findings from 2 reviews · compare the 2 reviews

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 2285 participants
Moderate
(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 5809 participants
Low

Summary of findings: insulin detemir vs NPH insulin

Health‐related quality of life

2 findings from 2 reviews · compare the 2 reviews

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 870 participants
Low
(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 873 participants
Very low

Summary of findings: insulin detemir vs NPH insulin

HbA1c (%)

2 findings from 2 reviews · compare the 2 reviews

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 3122 participants
Moderate
(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 2233 participants
Low

Insulin glargine vs NPH insulin

All‐cause mortality

2 findings from 2 reviews · compare the 2 reviews

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
0.14 [0, 6.98]
8 studies · 2175 participants
Moderate
(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
Peto OR 1.06 [0.62, 1.82]
14 studies · 6173 participants
Low